Paper Details

  1. Home
  2. Paper Details

Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.

Author: , AnXin, BiXi-Wen, CaiLi, CaoYe, ChenQian-Jun, GuoYing, HeZhen-Yu, HongRuo-Xi, HuaXin, HuangHeng, HuangJia-Jia, HuangZhang-Zan, JiangKui-Kui, KeYong-Li, LiJi-Bin, LinHuan-Xin, LinYing, LiuXin-Mei, PangDan-Mei, PengRou-Jun, ShiWei, ShiYan-Xia, SongChen-Ge, SuYan-Hong, TangJun, WangShu-Sen, WangXi, WangXian-Ming, WangXin-Yue, XiaWen, XuFei, XueCong, YuanZhong-Yu, ZengJian, ZhangAn-Qin, ZhangLe-Hong, ZhaoLi, ZhongYong-Yi

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This randomized clinical trial of 443 women with early-stage triple-negative breast cancer evaluated the efficacy of low-dose capecitabine maintenance therapy for 1 year after standard adjuvant chemotherapy. Capecitabine maintenance significantly improved 5-year disease-free survival compared to observation. The most common capecitabine-related adverse event was hand-foot syndrome.
Paper Details　
Original Abstract of the Article :
IMPORTANCE: Among all subtypes of breast cancer, triple-negative breast cancer has a relatively high relapse rate and poor outcome after standard treatment. Effective strategies to reduce the risk of relapse and death are needed. OBJECTIVE: To evaluate the efficacy and adverse effects of low-dose c...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729589/

データ提供：米国国立医学図書館（NLM）

Capecitabine: A Potential New Hope for Triple-Negative Breast Cancer Patients

Triple-negative breast cancer presents a significant challenge due to its aggressive nature and limited treatment options. This clinical trial investigated the efficacy of low-dose capecitabine maintenance therapy in reducing the risk of relapse and improving survival rates for patients with early-stage triple-negative breast cancer. The researchers aimed to explore the potential benefits of capecitabine in preventing disease recurrence and enhancing overall survival.

Capecitabine Maintenance Therapy: A Promising Strategy for Triple-Negative Breast Cancer

The results demonstrate that low-dose capecitabine maintenance therapy significantly improved 5-year disease-free survival compared to observation alone. This finding suggests that capecitabine may be a valuable addition to standard adjuvant chemotherapy for patients with early-stage triple-negative breast cancer. The study provides evidence for the potential of capecitabine in reducing the risk of relapse and improving long-term outcomes for these patients.

Boosting Survival Rates: A New Hope for Triple-Negative Breast Cancer Patients

The study's findings offer a glimmer of hope for patients with triple-negative breast cancer. Capecitabine maintenance therapy demonstrates the potential to enhance survival rates and improve long-term outcomes. This research emphasizes the importance of exploring new treatment strategies and finding effective ways to combat this aggressive form of breast cancer.

Dr. Camel's Conclusion

This clinical trial provides valuable insights into the potential of capecitabine maintenance therapy in managing triple-negative breast cancer. The study's findings suggest that capecitabine may be a promising addition to standard treatment, offering hope for improving survival rates and reducing relapse risks for patients with this challenging disease. It underscores the need for continued research to develop more effective treatments for triple-negative breast cancer and improve outcomes for patients.

Date :
  1. Date Completed 2021-01-27
  2. Date Revised 2022-04-22
Further Info :

Pubmed ID

33300950

DOI: Digital Object Identifier

PMC7729589

Related Literature

Article Analysis
・Effective treatment of breast cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.